Adage Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-84,390	Closed	-$27.5M	–	877
2025 Q2	$27.5M	Sell	84,390 -197,794	-70%	-$54.7M	0.05%	367
2025 Q1	$76.2M	Buy	282,184 +189,128	+203%	+$48.6M	0.14%	145
2024 Q4	$21.9M	Sell	93,056 -22,944	-20%	-$6.03M	0.04%	423
2024 Q3	$31.9M	Sell	116,000 -138,000	-54%	-$35.9M	0.06%	323
2024 Q2	$61.7M	Buy	+254,000	New	+$40.1M	0.11%	184
2022 Q4	–	Sell	-485,000	Closed	-$97.1M	–	978
2022 Q3	$97.1M	Buy	485,000 +315,000	+185%	+$60.1M	0.24%	100
2022 Q2	$24.8M	Buy	170,000 +97,700	+135%	+$13.9M	0.06%	357
2022 Q1	$11.8M	Sell	72,300 -60,000	-45%	-$9.14M	0.02%	649
2021 Q4	$22.4M	Buy	+132,300	New	+$24.6M	0.04%	422
2018 Q2	–	Sell	-240,000	Closed	-$28.6M	–	732
2018 Q1	$28.6M	Sell	240,000 -50,000	-17%	-$6.45M	0.07%	324
2017 Q4	$36.8M	Buy	+290,000	New	+$36.4M	0.08%	281